We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Regeneron (REGN) Gets FDA Nod for Praluent Label Extension
Read MoreHide Full Article
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) announced that the FDA extended the approval of the cholesterol drug Praluent’s (alirocumab) label.
The regulatory body approved the drug as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowering therapies to include pediatric patients aged eight and older with heterozygous familial hypercholesterolemia (HeFH).
The approval is based on a phase III, randomized multi-center trial evaluating pediatric patients aged 8 to 17 with HeFH, who had LDL-C levels of 130mg/dL or greater and were already being treated with lipid-lowering medications. Patients were randomized to receive Praluent or placebo every two or four weeks in two consecutive cohorts.
Patients who received Praluent every four weeks had a 31% lower LDL-C than placebo at 24 weeks. Improvements in additional key lipid parameters were also observed.
Familial hypercholesterolemia (FH) is an inherited condition caused by mutations in one of several genes that control how the body processes cholesterol, which can lead to high levels of LDL-C (bad cholesterol).
FH can come in two forms — HeFH, which develops when one mutated gene is inherited from one parent, and homozygous familial hypercholesterolemia (HoFH), which develops when a mutated gene is inherited from both parents. Praluent is approved to treat both children and adults with HeFH and adults with HoFH.
Praluent is already indicated in the United States to reduce the risk of myocardial infarction, stroke and unstable angina requiring hospitalization in adults with established cardiovascular disease. The drug is indicated as an adjunct to diet, alone or in combination with other low-density LDL-C lowering therapies in adults with primary hyperlipidemia, including HeFH to reduce LDL-C.
Praluent raked in sales of $638.9 million in 2023.
Regeneron’s shares have jumped 28.3% in the past year against the industry’s decline of 4.6%.
Image Source: Zacks Investment Research
The company records net product sales of Praluent in the United States, while partner Sanofi (SNY - Free Report) records net product sales of Praluent outside the United States and pays Regeneron a royalty on such sales.
REGN also has a collaboration with Sanofi for the asthma drug Dupixent.
Regeneron’s fourth-quarter sales and earnings beat estimates, but lead drug Eylea’s sales declined year over year in the fourth quarter. Eylea sales were under pressure in 2023 due to competition from Roche’s Vabysmo.
Nevertheless, REGN should benefit from Dupixent’s continued label expansions and solid demand. The approval of Eylea HD is also a great boost, generating incremental revenues for the company. Regeneron’s progress with the oncology portfolio is also impressive.
In the past 30 days, the Zacks Consensus Estimate for ADMA Biologics’ 2024 earnings per share (EPS) has increased from 22 cents to 30 cents. During the same period, the estimate for ADMA’s 2025 EPS has increased from 32 cents to 50 cents. Over the past year, ADMA shares have surged 97.5%.
In the past 30 days, the Zacks Consensus Estimate for FibroGen’s 2024 loss per share has narrowed from $1.14 to $1.09. During the same period, the estimate for the company’s 2025 loss per share is pegged at 6 cents.
FGEN beat estimates in two of the trailing four quarters, missing the mark on the other two occasions, delivering an average negative surprise of 2.26%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Regeneron (REGN) Gets FDA Nod for Praluent Label Extension
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) announced that the FDA extended the approval of the cholesterol drug Praluent’s (alirocumab) label.
The regulatory body approved the drug as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowering therapies to include pediatric patients aged eight and older with heterozygous familial hypercholesterolemia (HeFH).
The approval is based on a phase III, randomized multi-center trial evaluating pediatric patients aged 8 to 17 with HeFH, who had LDL-C levels of 130mg/dL or greater and were already being treated with lipid-lowering medications. Patients were randomized to receive Praluent or placebo every two or four weeks in two consecutive cohorts.
Patients who received Praluent every four weeks had a 31% lower LDL-C than placebo at 24 weeks. Improvements in additional key lipid parameters were also observed.
Familial hypercholesterolemia (FH) is an inherited condition caused by mutations in one of several genes that control how the body processes cholesterol, which can lead to high levels of LDL-C (bad cholesterol).
FH can come in two forms — HeFH, which develops when one mutated gene is inherited from one parent, and homozygous familial hypercholesterolemia (HoFH), which develops when a mutated gene is inherited from both parents. Praluent is approved to treat both children and adults with HeFH and adults with HoFH.
Praluent is already indicated in the United States to reduce the risk of myocardial infarction, stroke and unstable angina requiring hospitalization in adults with established cardiovascular disease. The drug is indicated as an adjunct to diet, alone or in combination with other low-density LDL-C lowering therapies in adults with primary hyperlipidemia, including HeFH to reduce LDL-C.
Praluent raked in sales of $638.9 million in 2023.
Regeneron’s shares have jumped 28.3% in the past year against the industry’s decline of 4.6%.
Image Source: Zacks Investment Research
The company records net product sales of Praluent in the United States, while partner Sanofi (SNY - Free Report) records net product sales of Praluent outside the United States and pays Regeneron a royalty on such sales.
REGN also has a collaboration with Sanofi for the asthma drug Dupixent.
Regeneron’s fourth-quarter sales and earnings beat estimates, but lead drug Eylea’s sales declined year over year in the fourth quarter. Eylea sales were under pressure in 2023 due to competition from Roche’s Vabysmo.
Nevertheless, REGN should benefit from Dupixent’s continued label expansions and solid demand. The approval of Eylea HD is also a great boost, generating incremental revenues for the company. Regeneron’s progress with the oncology portfolio is also impressive.
REGN currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the drug/biotech industry are ADMA Biologics (ADMA - Free Report) and FibroGen (FGEN - Free Report) . ADMA sports a Zacks Rank #1 (Strong Buy) and FGEN carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 30 days, the Zacks Consensus Estimate for ADMA Biologics’ 2024 earnings per share (EPS) has increased from 22 cents to 30 cents. During the same period, the estimate for ADMA’s 2025 EPS has increased from 32 cents to 50 cents. Over the past year, ADMA shares have surged 97.5%.
In the past 30 days, the Zacks Consensus Estimate for FibroGen’s 2024 loss per share has narrowed from $1.14 to $1.09. During the same period, the estimate for the company’s 2025 loss per share is pegged at 6 cents.
FGEN beat estimates in two of the trailing four quarters, missing the mark on the other two occasions, delivering an average negative surprise of 2.26%.